Home ETF List About

Portfolio Holdings Detail for ISIN IE000G2LIHG9
Stock Name / FundiShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity Type
Entity LEI 549300ZP07LMR36K1T02
ETF TickerSAUA(EUR) ETF Plus

Holdings detail for REGN

Stock NameRegeneron Pharmaceuticals Inc
TickerREGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75886F1075
LEI549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN
In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc) REGN holdings

DateNumber of REGN Shares HeldBase Market Value of REGN SharesLocal Market Value of REGN SharesChange in REGN Shares HeldChange in REGN Base ValueCurrent Price per REGN Share HeldPrevious Price per REGN Share Held
2025-09-30 (Tuesday)32,648USD 18,356,991USD 18,356,991
2025-09-29 (Monday)32,137USD 18,020,823USD 18,020,823
2025-09-26 (Friday)32,004REGN holding increased by 301USD 18,047,056REGN holding increased by 435722USD 18,047,056301USD 435,722 USD 563.9 USD 555.51
2025-09-25 (Thursday)31,703REGN holding increased by 21USD 17,611,334REGN holding decreased by -668546USD 17,611,33421USD -668,546 USD 555.51 USD 576.98
2025-09-24 (Wednesday)31,682REGN holding increased by 399USD 18,279,880REGN holding decreased by -449565USD 18,279,880399USD -449,565 USD 576.98 USD 598.71
2025-09-18 (Thursday)31,283REGN holding increased by 84USD 18,729,445REGN holding increased by 462430USD 18,729,44584USD 462,430 USD 598.71 USD 585.5
2025-09-17 (Wednesday)31,199REGN holding increased by 105USD 18,267,015REGN holding increased by 386099USD 18,267,015105USD 386,099 USD 585.5 USD 575.06
2025-09-16 (Tuesday)31,094REGN holding increased by 168USD 17,880,916REGN holding increased by 172998USD 17,880,916168USD 172,998 USD 575.06 USD 572.59
2025-09-15 (Monday)30,926REGN holding increased by 56USD 17,707,918REGN holding increased by 420718USD 17,707,91856USD 420,718 USD 572.59 USD 560
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE000G2LIHG9

Show aggregate share trades of REGN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-26BUY301 563.900* 649.01
2025-09-25BUY21 555.510* 649.47
2025-09-24BUY399 576.980* 649.83
2025-09-18BUY84 598.710* 650.09
2025-09-17BUY105 585.500* 650.41
2025-09-16BUY168 575.060* 650.79
2025-09-15BUY56 572.590* 651.18
2025-09-11SELL-7 568.200* 652.07 Profit of 4,565 on sale
2025-09-10BUY448 555.830* 652.57
2025-09-09BUY28 556.530* 653.06
2025-08-06BUY131 555.130* 654.06
2025-07-31BUY35 545.460* 655.07
2025-07-29BUY140 558.145* 656.12
2025-07-28BUY28 558.630* 656.64
2025-07-25BUY42 563.100* 657.15
2025-07-24BUY20 564.640* 657.65
2025-07-23BUY49 572.390* 658.11
2025-07-22BUY28 560.930* 658.64
2025-07-18BUY56 542.520* 659.28
2025-07-17BUY42 550.000* 659.88
2025-07-11BUY56 567.740* 662.17
2025-07-10BUY63 559.760* 662.75
2025-07-09BUY63 552.580* 663.38
2025-07-07SELL-42 538.110* 664.78 Profit of 27,921 on sale
2025-07-02SELL-175 547.740* 666.85 Profit of 116,698 on sale
2025-06-27BUY21 521.000* 668.56
2025-06-26BUY21 521.000* 669.44
2025-06-24SELL-98 522.270* 671.24 Profit of 65,781 on sale
2025-06-18BUY56 513.580* 675.19
2025-06-17BUY21 508.860* 676.23
2025-06-16SELL-29 522.680* 677.19 Profit of 19,639 on sale
2025-06-13BUY60 529.240* 678.13
2025-06-12SELL-35 521.840* 679.13 Profit of 23,769 on sale
2025-06-11BUY77 518.600* 680.16
2025-06-06BUY21 493.220* 683.46
2025-06-05BUY98 483.070* 684.78
2025-06-04BUY14 484.930* 686.11
2025-06-03SELL-7 487.860* 687.43 Profit of 4,812 on sale
2025-05-30SELL-854 490.280* 690.09 Profit of 589,335 on sale
2025-05-29BUY17 605.390* 690.66
2025-05-27BUY119 603.260* 691.95
2025-05-23BUY90 588.340* 693.40
2025-05-22BUY49 596.850* 694.08
2025-05-19BUY42 596.540* 695.99
2025-05-16BUY21 594.320* 696.73
2025-05-15SELL-14 584.990* 697.55 Profit of 9,766 on sale
2025-05-14BUY7 571.360* 698.47
2025-05-13BUY14 574.160* 699.39
2025-05-12BUY49 575.630* 700.32
2025-05-09SELL-35 527.780* 701.62 Profit of 24,557 on sale
2025-05-08BUY14 547.670* 702.78
2025-05-07BUY21 560.930* 703.86
2025-05-02BUY777 605.610* 706.55
2025-04-30BUY245 598.760* 708.33
2025-04-29BUY60 568.910* 709.45
2025-04-28BUY49 610.860* 710.24
2025-04-25BUY126 602.640* 711.12
2025-04-24SELL-147 599.760* 712.03 Profit of 104,668 on sale
2025-04-23BUY133 587.850* 713.06
2025-04-22BUY56 585.490* 714.12
2025-04-17BUY77 563.160* 718.00
2025-04-15BUY70 557.910* 720.86
2025-04-11BUY112 554.180* 723.66
2025-04-09BUY42 576.720* 726.58
2025-04-08BUY252 556.810* 728.13
2025-04-07BUY81 572.780* 729.55
2025-04-04SELL-112 573.450* 731.00 Profit of 81,872 on sale
2025-04-02BUY952 625.600* 731.98
2025-04-01BUY7 617.000* 733.07
2025-03-31BUY49 634.230* 734.01
2025-03-28BUY28 637.360* 734.94
2025-03-27BUY12 635.830* 735.90
2025-03-26BUY7 640.140* 736.84
2025-03-25BUY75 634.140* 737.86
2025-03-24BUY78 661.000* 738.63
2025-03-21SELL-28 658.480* 739.43 Profit of 20,704 on sale
2025-03-20BUY112 662.620* 740.22
2025-03-19BUY18 672.360* 740.92
2025-03-18BUY232 664.960* 741.71
2025-03-17BUY49 678.420* 742.38
2025-03-14BUY364 666.870* 743.18
2025-03-13BUY70 680.610* 743.85
2025-03-12SELL-350 689.500* 744.44 Profit of 260,555 on sale
2025-03-11SELL-259 718.160* 744.73 Profit of 192,885 on sale
2025-03-10BUY77 744.830* 744.73
2025-03-07BUY14 707.510* 745.15
2025-03-05BUY105 687.150* 745.81
2025-03-04BUY119 675.490* 746.62
2025-03-03BUY224 684.870* 747.33
2025-02-28BUY182 698.740* 747.91
2025-02-27SELL-35 702.780* 748.44 Profit of 26,195 on sale
2025-02-25BUY259 723.470* 749.25
2025-02-21BUY28 700.330* 750.31
2025-02-18SELL-63 680.000* 752.77 Profit of 47,425 on sale
2025-02-14SELL-427 673.600* 754.88 Profit of 322,336 on sale
2025-02-13BUY7 674.270* 755.97
2025-02-12BUY68 663.860* 757.24
2025-02-07SELL-12 710.000* 760.18 Profit of 9,122 on sale
2025-02-06BUY133 722.070* 760.73
2025-02-05BUY35 716.720* 761.38
2025-02-04BUY42 697.050* 762.34
2025-02-03BUY42 666.850* 763.78
2025-01-31BUY77 672.980* 765.18
2025-01-29SELL-7 687.270* 767.72 Profit of 5,374 on sale
2025-01-28SELL-63 686.330* 769.03 Profit of 48,449 on sale
2025-01-27SELL-112 684.710* 770.41 Profit of 86,286 on sale
2025-01-24BUY84 675.790* 771.99
2025-01-23BUY14 694.640* 773.30
2025-01-22BUY112 680.030* 774.91
2025-01-21BUY84 687.800* 776.44
2025-01-16BUY121 693.230* 781.49
2025-01-14BUY56 690.870* 784.74
2025-01-10BUY168 696.880* 787.85
2024-12-30BUY21 702.590* 795.45
2024-12-27BUY28 712.400* 797.34
2024-12-23BUY210 715.130* 803.33
2024-12-20BUY56 701.850* 805.87
2024-12-19BUY7 708.250* 808.37
2024-12-18BUY56 714.620* 810.84
2024-12-17BUY14 740.010* 812.75
2024-12-16BUY70 724.870* 815.19
2024-12-13BUY46 731.300* 817.59
2024-12-10BUY350 778.500* 820.13
2024-12-09BUY42 788.000* 821.13
2024-12-06SELL-105 778.000* 822.52 Profit of 86,365 on sale
2024-12-05SELL-7 767.900* 824.34 Profit of 5,770 on sale
2024-12-03BUY35 749.570* 829.52
2024-11-27SELL-42 754.870* 841.84 Profit of 35,357 on sale
2024-11-26BUY147 753.030* 845.70
2024-11-25BUY17 749.510* 850.07
2024-11-22SELL-12 738.000* 855.41 Profit of 10,265 on sale
2024-11-21SELL-35 744.500* 860.96 Profit of 30,133 on sale
2024-11-20SELL-14 743.350* 867.15 Profit of 12,140 on sale
2024-11-19BUY7 744.600* 873.95
2024-11-18BUY60 762.000* 880.54
2024-11-11BUY21 825.680* 888.17
2024-11-07BUY17 824.480* 897.66
2024-11-06BUY168 816.650* 904.41
2024-11-05BUY35 829.430* 911.23
2024-11-04BUY12 828.840* 919.47
2024-11-01BUY18 843.600* 927.90
2024-10-30SELL-42 922.790* 941.44 Profit of 39,541 on sale
2024-10-29SELL-126 927.330* 943.79 Profit of 118,918 on sale
2024-10-28SELL-49 928.610* 946.83 Profit of 46,395 on sale
2024-10-21SELL-7 968.500* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19208,6591,635312,81266.7%
2025-09-18236,4853,679387,51961.0%
2025-09-17229,191716370,89561.8%
2025-09-16173,632584271,02064.1%
2025-09-15204,491251334,49661.1%
2025-09-12117,50433222,76052.7%
2025-09-11125,4783,137286,51643.8%
2025-09-10195,068481339,88557.4%
2025-09-09129,168994274,52047.1%
2025-09-08250,895396527,06247.6%
2025-09-05170,149290289,56658.8%
2025-09-04188,2272,103360,61952.2%
2025-09-03185,679344438,11142.4%
2025-09-02191,954138476,28840.3%
2025-08-29133,226685236,72656.3%
2025-08-28116,5602,177256,67545.4%
2025-08-27113,719465243,83646.6%
2025-08-26210,376450400,19952.6%
2025-08-25149,13068363,37741.0%
2025-08-22211,8223,244701,77030.2%
2025-08-21257,4923,416446,43957.7%
2025-08-20327,738572559,13358.6%
2025-08-19118,4722,191324,31136.5%
2025-08-18146,282388277,90952.6%
2025-08-15209,9233,375441,75247.5%
2025-08-14157,5693,623429,32736.7%
2025-08-13111,342233362,78630.7%
2025-08-12117,647171310,77537.9%
2025-08-11129,5132,676284,75745.5%
2025-08-08128,5591,038431,84129.8%
2025-08-07166,6481,560352,87747.2%
2025-08-06176,311624397,08944.4%
2025-08-05154,257115353,74443.6%
2025-08-04200,7581,913409,89749.0%
2025-08-01349,7753,745728,72048.0%
2025-07-31222,350476549,34440.5%
2025-07-30106,8391,689231,76146.1%
2025-07-29149,359276292,66751.0%
2025-07-28103,6871,380245,28742.3%
2025-07-25103,783556259,06940.1%
2025-07-24156,9742,397291,67753.8%
2025-07-23168,7341,708355,37247.5%
2025-07-22116,324617304,88038.2%
2025-07-2198,482900250,10739.4%
2025-07-18183,1741,051391,90946.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.